Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.43 |
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 3/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3662668 | 0.86 | HTR6 (0.42) | HTR6ENPP3ENPP1PKMSRC | |
| SCHEMBL678731 | 0.83 | IP6K1 (0.38) | HTR6ENPP3ENPP1PKMSRC | |
| SCHEMBL675465 | 0.83 | IP6K1 (0.38) | HTR6ENPP3ENPP1PKMSRC | |
| SCHEMBL676525 | 0.83 | GRM4 (0.39) | ENPP3ENPP1PKMSRCSMN1; SMN2 | |
| SCHEMBL675896 | 0.82 | SRC (0.40) | HTR6ENPP3ENPP1PKMSRC | |
| SCHEMBL675512 | 0.81 | PTGDR2 (0.48) | HTR6PKMRXFP1SRCALDH1A1 | |
| SCHEMBL675466 | 0.81 | ENPP3 (0.38) | HTR6ENPP3ENPP1PKMSRC | |
| SCHEMBL3664606 | 0.80 | ALDH1A1 (0.37) | ENPP3ENPP1PKMSRCSMN1; SMN2 | |
| SCHEMBL677032 | 0.79 | HTR6 (0.42) | HTR6KDM4EALDH1A1PTGDR2MAPT | |
| SCHEMBL675276 | 0.79 | HTR6 (0.43) | HTR6SRCKDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | claimed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | claimed |
| EP-3885348-A1 | NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR | Korea Research Institute of Chemical Technology (KR) | 2021-09-29 | — | — | EP | disclosed |
| EP-2855475-B1 | ALPHA-CARBOLINES FOR THE TREATMENT OF CANCER | UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) | 2017-06-28 | — | — | EP | disclosed |
| EP-2855475-B1 | ALPHA-CARBOLINES FOR THE TREATMENT OF CANCER | UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) | 2017-06-28 | — | — | EP | disclosed |
| US-9428500-B2 | Alpha-carbolines for the treatment of cancer | UNIVERSITA DEGLI STUDI DI MILANO—BICOCCA (IT) | 2016-08-30 | — | — | US | disclosed |
| US-9428500-B2 | Alpha-carbolines for the treatment of cancer | UNIVERSITA DEGLI STUDI DI MILANO—BICOCCA (IT) | 2016-08-30 | — | — | US | disclosed |
| US-20150105554-A1 | ALPHA-CARBOLINES FOR THE TREATMENT OF CANCER | UNIVERSITE DE GENEVE (CH) | 2015-04-16 | — | — | US | disclosed |
| US-20150105554-A1 | ALPHA-CARBOLINES FOR THE TREATMENT OF CANCER | UNIVERSITE DE GENEVE (CH) | 2015-04-16 | — | — | US | disclosed |
| EP-2855475-A1 | ALPHA-CARBOLINES FOR THE TREATMENT OF CANCER | Università Degli Studi Di Milano - Bicocca (IT) | 2015-04-08 | — | — | EP | disclosed |
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| WO-2013167730-A1 | ALPHA-CARBOLINES FOR THE TREATMENT OF CANCER | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013167730-A1 | ALPHA-CARBOLINES FOR THE TREATMENT OF CANCER | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2013-11-14 | — | — | WO | disclosed |
| EP-2662372-A1 | Alpha-carbolines for the treatment of cancer | Università Degli Studi Di Milano - Bicocca (IT) | 2013-11-13 | — | — | EP | disclosed |
| EP-2662372-A1 | Alpha-carbolines for the treatment of cancer | Università Degli Studi Di Milano - Bicocca (IT) | 2013-11-13 | — | — | EP | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| EP-2161271-A1 | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl | Università Degli Studi Di Milano - Bicocca (IT) | 2010-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105554-A1 | ALPHA-CARBOLINES FOR THE TREATMENT OF CANCER | ALK, CSNK1A1, BRAF | HTR6 3864/4885KRAS 13/4885ENPP3 4062/4885 |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | HTR6 4762/4885KRAS 26/4885ENPP3 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.